Skip to main content
. 2016 Feb 26;60(3):1584–1591. doi: 10.1128/AAC.02657-15

FIG 2.

FIG 2

Humanized dosing regimens of vancomycin against MRSA USA400 quantifying the total population (blue) and the sequential emergence of resistance secondary to drug exposure (red, gray, and pink) over a 10-day period.